You are here
Home > Autolus

Autolus Announces Pricing of Initial Public Offering

Autolus Announces Pricing of Initial Public Offering LONDON – 22 June, 2018 – Autolus Therapeutics plc (“Autolus”), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced the pricing of its initial public offering in the United States of 8,823,530 American Depositary Shares (“ADSs”) representing 8,823,530 ordinary shares at an initial public offering […]

Top